These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167 [TBL] [Abstract][Full Text] [Related]
67. Propensity score-based analysis of long-term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support. Numan L; Ramjankhan FZ; Oberski DL; Oerlemans MIFJ; Aarts E; Gianoli M; Van Der Heijden JJ; De Jonge N; Van Der Kaaij NP; Meuwese CL; Mokhles MM; Oppelaar AM; De Waal EEC; Asselbergs FW; Van Laake LW ESC Heart Fail; 2021 Apr; 8(2):1596-1603. PubMed ID: 33635573 [TBL] [Abstract][Full Text] [Related]
68. Advanced heart failure treated with continuous-flow left ventricular assist device. Slaughter MS; Rogers JG; Milano CA; Russell SD; Conte JV; Feldman D; Sun B; Tatooles AJ; Delgado RM; Long JW; Wozniak TC; Ghumman W; Farrar DJ; Frazier OH; N Engl J Med; 2009 Dec; 361(23):2241-51. PubMed ID: 19920051 [TBL] [Abstract][Full Text] [Related]
73. Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device. Mehra MR; Nayak A; Morris AA; Lanfear DE; Nemeh H; Desai S; Bansal A; Guerrero-Miranda C; Hall S; Cleveland JC; Goldstein DJ; Uriel N; Chen L; Bailey S; Anyanwu A; Heatley G; Chuang J; Estep JD JACC Heart Fail; 2022 Dec; 10(12):948-959. PubMed ID: 36456068 [TBL] [Abstract][Full Text] [Related]
74. Third-generation continuous-flow left ventricular assist devices: a comparative outcome analysis by device type. Mihalj M; Heinisch PP; Schober P; Wieser M; Martinelli M; de By TMMH; Schefold JC; Luedi MM; Kadner A; Carrel T; Mohacsi P; Hunziker L; Reineke D ESC Heart Fail; 2022 Oct; 9(5):3469-3482. PubMed ID: 35880515 [TBL] [Abstract][Full Text] [Related]
75. Quality of life metrics in LVAD patients after hemocompatibility-related adverse events. Weber MP; Stulak J; Maltais S; Pagani FD; Cowger J; Tchantchaleishvili V Artif Organs; 2022 Aug; 46(8):1616-1625. PubMed ID: 35315092 [TBL] [Abstract][Full Text] [Related]
76. Hemocompatibility of Axial Versus Centrifugal Pump Technology in Mechanical Circulatory Support Devices. Schibilsky D; Lenglinger M; Avci-Adali M; Haller C; Walker T; Wendel HP; Schlensak C Artif Organs; 2015 Aug; 39(8):723-8. PubMed ID: 26234452 [TBL] [Abstract][Full Text] [Related]
77. Factors Related to Pump Thrombosis With the Heartmate II Left Ventricular Assist Device. Klodell CT; Massey HT; Adamson RM; Dean DA; Horstmanshof DA; Ransom JM; Salerno CT; Cowger JA; Aranda JM; Chen L; Long JW; Dembitsky W J Card Surg; 2015 Oct; 30(10):775-80. PubMed ID: 26283153 [TBL] [Abstract][Full Text] [Related]
78. Results of the European clinical trial of Arrow CorAide left ventricular assist system. Saeed D; Arusoglu L; Gazzoli F; Hetzer R; Morshius M; Alloni A; Viganò M; Koerfer R; Golding LA; El Banayosy A Artif Organs; 2013 Feb; 37(2):121-7. PubMed ID: 23043450 [TBL] [Abstract][Full Text] [Related]
79. Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre. Mueller M; Hoermandinger C; Richter G; Mulzer J; Tsyganenko D; Krabatsch T; Starck C; Stein J; Schoenrath F; Falk V; Potapov E Eur J Cardiothorac Surg; 2020 Jun; 57(6):1160-1165. PubMed ID: 32298426 [TBL] [Abstract][Full Text] [Related]
80. COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device. Allen SR; Slaughter MS; Ahmed MM; Bartoli CR; Dhingra R; Egnaczyk GF; Gulati SK; Kiernan MS; Mahr C; Meyer DM; Motomura T; Ono M; Ravichandran A; Shafii A; Smith J; Soleimani B; Toyoda Y; Yarboro LT; Dowling RD J Heart Lung Transplant; 2023 Jan; 42(1):33-39. PubMed ID: 36347767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]